{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T06:31:32Z","timestamp":1778308292511,"version":"3.51.4"},"reference-count":14,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"33","license":[{"start":{"date-parts":[[2020,8,14]],"date-time":"2020-08-14T00:00:00Z","timestamp":1597363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Medical Scientific Research Foundation of Hebei Province","award":["20150313"],"award-info":[{"award-number":["20150313"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>Abstract<\/jats:title>\n            <jats:p>This study aimed to assess the prevalence and occult rates of uterine leiomyosarcoma (ULMS) in women with smooth-muscle tumors undergoing gynecological surgery. A retrospective study was performed at an academic cancer center from 2008 to 2015. Patients undergoing either hysterectomy or myomectomy via laparoscopic, abdominal, vaginal, and hysteroscopic approaches were identified with the validated pathology diagnosis of either ULMS or leiomyomas. All patients initially operated at our institute were included and reviewed. The prevalence and occult rates of ULMS were calculated and compared between different age groups.<\/jats:p>\n            <jats:p>Twenty-eight patients with original ULMS were identified in 9556 gynecological surgeries. The prevalence of overall and occult ULMS in our study was 0.25% (1 in 345 patients) and 0.07% (1 in 1429 patients). The proportion of occult in all ULMSs was 25%. The prevalence rates of overall ULMS were 0.21%, 0.13%, 0.52%, 2.12%, and 6.67% in the 30 to 39, 40 to 49, 50 to 59, 60 to 69, and \u226570-year age groups, respectively. There was a significantly increased risk of ULMS after 50 years of age. The prevalence rates of occult ULMS were 0.05%, 0.08%, and 0.12% for the 30 to 39, 40 to 49, and 50 to 59 year age groups, respectively. There was no statistically significant difference among age the groups. The prevalence of ULMS was 0.41% and 0.16% for solitary and multiple tumor masses, respectively. Patients with solitary uterine tumors were at a significantly increased risk of ULMS (OR\u200a=\u200a2.601, 95% CI\u200a=\u200a1.108\u20136.141).<\/jats:p>\n            <jats:p>Our retrospective data in part reflects the clinical characteristics of overall and occult ULMS and forms the basis for further prevention of occult ULMS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000021766","type":"journal-article","created":{"date-parts":[[2020,8,13]],"date-time":"2020-08-13T06:10:29Z","timestamp":1597299029000},"page":"e21766","source":"Crossref","is-referenced-by-count":23,"title":["Prevalence and occult rates of uterine leiomyosarcoma"],"prefix":"10.1097","volume":"99","author":[{"given":"Lingxiang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Gynecology"},{"name":"Cancer Institute, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Hebei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shumei","family":"Li","sequence":"additional","affiliation":[{"name":"Cancer Institute, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Hebei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhengmao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gynecology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingde","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Gynecology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Baoen","family":"Shan","sequence":"additional","affiliation":[{"name":"Cancer Institute, Hebei Medical University Fourth Affiliated Hospital and Hebei Provincial Tumor Hospital, Hebei, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2020,8,14]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.1002\/ijc.22239","article-title":"Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemiology and end results program, 1978\u20132001: an analysis of 26,758 cases","volume":"119","author":"Toro","year":"2010","journal-title":"Int J Cancer"},{"issue":"(S4)","key":"R2-20230915","first-page":"1702","article-title":"Prognostic factors in early-stage uterine sarcoma: a gynecologic oncology group study","volume":"71","author":"Major","year":"2015","journal-title":"Cancer"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1097\/IGC.0000000000000290","article-title":"Uterine leiomyosarcoma: a review article","volume":"24","author":"Gockley","year":"2014","journal-title":"Int J Gynecol Cancer"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s00404-018-4949-4","article-title":"Incidence and groups at risk for unexpected uterine leiomyosarcoma: a Dutch nationwide cohort study","volume":"299","author":"Van Den Haak","year":"2019","journal-title":"Arch Gynecol Obstet"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1046\/j.1525-1438.2002.01086.x","article-title":"Usefulness of Gd-DTPA contrast-enhanced dynamic MRI and serum determination of LDH and its isozymes in the differential diagnosis of leiomyosarcoma from degenerated leiomyoma of the uterus","volume":"12","author":"Goto","year":"2002","journal-title":"Int J Gynecol Cancer"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ygyno.2009.09.023","article-title":"Uterine sarcomas: a review","volume":"116","author":"D\u2019Angelo","year":"2010","journal-title":"Gynecol Oncol"},{"key":"R7-20230915","first-page":"414","article-title":"Uterine sarcoma in patients operated on for presumed leiomyoma and rapidly growing leiomyoma","volume":"83","author":"Parker","year":"1994","journal-title":"Obstet Gynecol"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.jmig.2015.11.012","article-title":"Uterine sarcomas in patients undergoing surgery for presumed leiomyomas: 10 years\u2019 experience","volume":"23","author":"Paul","year":"2016","journal-title":"J Minim Invasive Gynecol"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/AOG.0000000000002035","article-title":"Changes in myomectomy practice after the US Food and Drug Administration safety communication on power morcellation","volume":"129","author":"Stentz","year":"2017","journal-title":"Obstetrics & Gynecology"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.ejogrb.2015.11.009","article-title":"Incidence of occult leiomyosarcoma in presumed morcellation cases: a database study","volume":"197","author":"Rodriguez","year":"2016","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R11-20230915","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.2147\/CMAR.S208405","article-title":"Unexpected uterine sarcomas after hysterectomy and myomectomy for presumed leiomyoma: a retrospective study of 26,643 patients","volume":"11","author":"Cao","year":"2019","journal-title":"Cancer Manag Res"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1001\/jamasurg.2014.3518","article-title":"Population-based estimates of the prevalence of uterine sarcoma among patients with leiomyomata undergoing surgical treatment","volume":"150","author":"Mao","year":"2015","journal-title":"JAMA Surg"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ygyno.2015.01.025","article-title":"Preoperative patient stratification results in low rates of occult uterine malignancy in women undergoing uterine surgery and morcellation","volume":"137","author":"Ricci","year":"2015","journal-title":"Gynecol Oncol"},{"key":"R15-20230915","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ajog.2015.08.047","article-title":"Practice patterns and postoperative complications before and after US Food and Drug Administration safety communication on power morcellation","volume":"214","author":"Harris","year":"2016","journal-title":"Am J Obstet Gynecol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021766","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T01:15:29Z","timestamp":1694826929000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000021766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,14]]},"references-count":14,"journal-issue":{"issue":"33","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000021766","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,14]]}}}